DOCSLIB.ORG

Limiting Factors for Glycogen Storage in Tumors I. Limiting Enzymes *

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Limiting Factors for Glycogen Storage in Tumors I. Limiting Enzymes * Limiting Factors for Glycogen Storage in Tumors I. Limiting Enzymes * VIJA! N. NIGAM, HELEN L. MACDONALD,t AND A. CANTERO (Montreal Cancer Institute, Research Laboratories, Notre Dame Ho8pital and UniveraW de Montreal, Montreal, Canada) SUMMARY The paper presents a study of various enzymes involved in the final accumulation of glycogen in tumor tissues. The solid tumors used are : Novikoff hepatoma, Walker 256 carcinosarcoma, Sarcoma 37, leukemia, and melanoma. It was observed that tumor tissues showed lower activity of phosphoglucomutase and glycogen synthetase as compared with that of normal liver and muscle. All tumors studied except melanoma also showed decreased UDPG' pyrophosphorylase levels. Activities for ATP- and UTP-regenerating enzymes—namely, pyruvate kinase and nucleoside disphospho kinase—in tumors were close to those found in normal tissues, thus providing sufficient quantities of cofactors (ATP and UTP) and energy for the polymerization process. UDPG was not diverted to UDPGA in tumors because of the absence of UDPG dehy drogenase. The lesion could be best described as a defective system for glycogen syn thesis, owing to low activities of the enzymes involved in the synthetic process (phos phoglucomutase and glycogen synthetase) which were unable to accomplish efficient transformation of G-6-P to G-1-P and of UDPG to glycogen, in the presence of com peting high rates of tumor glycolysis and normal polysaccharide degradation by phosphorylase. The decreased content of glycogen, together perimental work, designed to explain the defi with high rates of glycolysis, has been observed in ciency of glycogen in tumor. most tumor tissues and reported extensively (1, The metabolic pathway through which glucose 11). Although a number of reports have appeared is finally converted to glycogen begins with its (1, 10, 12, 40) to explain the high rate of lactic phosphorylation to glucose-6-phosphate through acid production in tumors, the reasons for the lack hexokinase and adenosine triphosphate; next, its of glycogen accumulation have not been fully ex transformation to glucose 1-phosphate by phos plored. In the light of the new pathway for glyco phoglucomutase; and, fiuially, conversion of the gen synthesis mediated through uridine diphos glucose 1-phosphate to uridine diphosphate glu phate glucose, the problem is open for further ex cose in the presence of uridine triphosphate and UDPG-pyrophosphorylase (14).' The UDPG 5This work was supported by grants from the National Cancer Institute of Canada. formed can transfer its glucose moiety to a pre Presented at the meeting of American Society of Biological formed glycogen molecule through glycogen syn Chemists in Atlantic City, April 10, 1961. thetase (16), or it can undergo dehydrogenation to t Technical assistant. UDP-glucuronic acid (35) and later transfer the ‘Theabbreviations used are: AMP, adenosine monophos glucuronic acid moiety to a suitable acceptor form phate; ADP, adenosine diphosphate; ATP, adenosinetriphos ing a glucuronide. phate; UDP, uridine diphosphate; UTP, uridine triphosphate; Thus glycogen accumulation requires systems UDPG, uridine diphosphate glucose; UDPGA, uridine diphos phate glucuronic acid; G-1-P, glucose-i-phosphate; G-6-P, for the regeneration of UTP and G-1-P, and their glucose-6-phosphate; DPN, diphosphopyridine nucleotide; subsequent conversion to UDPG by UDPG pyro TPN, triphosphopyridine nucleotide; GDP, guanosine diphos phosphorylase, and the presence of glycogen syn phate; CDP, cytidine diphosphate; IDP, inosine diphosphate. thetase to accomplish the transfer of glucose resi Received for publication May 22, 1961. dues of UDPG to an existent glucose polymer. 131 Downloaded from cancerres.aacrjournals.org on September 24, 2021. © 1962 American Association for Cancer Research. 132 Cancer Research Vol. 22, February 1962 However, the presence of a synthesis system in BIocHEMIC@u@ PROCEDURES the tissue does not in itself provide for glycogen Glycogen synthetase was assayed according to storage, unless the glycogen-removing enzyme, Leloir and Goldemberg (16) in a system contain phosphorylase, is functioning at a normal or sub ing (in pmoles/0.115 ml), glycine buffer, pH 8.6, normal rate. 50; glucose-6-phosphate, pH 7, 0.825 ; UDPG, 0.5; This paper reports the activities of various en glycogen, 1 mg. ; and tissue homogenate, 0.01 ml. zymes responsible for the synthesis and degrada The digests were incubated at 87°C. for 10 mm tion of glycogen in tumor extracts, along with con utes and inactivated by boiling at 100° C. for 30 trol experiments on liver and muscle of both nor seconds, and the liberated UDP was estimated. mal and tumor-bearing animals. UDPG pyrophosphorylase digests consisted of MATERIALS AND METHODS (in @moles/3 ml), Tris-maleate buffer, pH 7.6, 100; UDPG, 1.25; magnesium chloride, 100; cysteine, CHEMICALS 1.59; TPN, 0.20; G-6-P dehydrogenase, 0.1 K The nucleotides (AMP, ADP, ATP, [JDP, units; phosphoglucomutase, 0.4 units; sodium py UDPG, DPN, TPN), sugar phosphates (G-1-P, rophosphate, 1.0; and 0.02 ml. of the supernatant G-6-P), G-6-P dehydrogenase Type IV, and pyru from a 10 per cent tissue homogenate. The control vate kinase were obtained from Sigma Chemical digest did not contain pyrophosphate. Equilibrium Co. Phosphopyruvate (tricyclohexyl amine salt) values were usually attained within 15—30minutes and myokinase were products of Mann Research of incubation at 37°C. The tumors, however, Laboratories, and rabbit liver glycogen of Nutri showed a lag period. The rise in extinction at 340 tional Biochemicals Corp. All other chemicals were m@ in the presence of TPN, phosphoglucomutase, the best reagent grade available from commercial and glucose-6-phosphate dehydrogenase was used sources. Crystalline phosphoglucomutase and as a measure of G-1-P concentration formed from adenylic acid deaminase were prepared according UDPG and pyrophosphate upon addition of the to Naj jar (24) and Kaickar (13), respectively. enzyme (22, 37). TRANSPLANTABLE MOUSE AND RAT TuMoRs Pi,ruvate kinase was measured by the system The studies reported here were carried out with employed for UDP or ADP estimation. The di the following tumors: Sarcoma 37 in white Swiss gests contained (in @imoles/0.5 ml) triethano mice, lymphatic leukemia in AKR mice, melanoma lamine buffer, pH 7.6, 30; phosphopyruvate, 0.9; in DBA/1J mice, Novikoff hepatoma in Sprague magnesium sulfate, 5 ; UDP or ADP, 0.1 ; and en Dawley rats, and Walker 256 carcinosarcoma in zyme supernatant, 0.05 ml. The pyruvate liberat Wistar rats. Normal mice and rats of the same ed was measured as a color complex with 2,4,- strain were used as control animals. dinitrophenyl hydrazine (16), after incubation at 370 C. for 15 mm. PREPARATION OF HOMOGENATES Nucleoside diphosphokinase was assayed ac AND SUPERNATANTS cording to the procedure of Berg and Joklik (4) The rats were stunned, decapitated, and bled, measuring ADP formation with myokinase and and the mice sacrificed by cervical dislocation. The adenylic acid deamiriase (23). livers, muscles, and tumors were quickly excised Phosphoglucomutase and UDPG dehydrogenase and placed in beakers surrounded by cracked ice. were assayed by procedures described by Najjar The tumors were freed as much as possible of ne (25) and Strominger et al. (36), respectively. crotic and connective tissue. Muscle was taken Phosphorylase activity was measured in the from the hind legs. Tissues were minced with scis presence and absence of 5'-AMP. The digests sors, and 10 per cent homogenates were prepared contained (in @imoles/ml), sodium citrate buffer, in ice-cold 0.25 M sucrose containing 0.001 M ver pH 5.9, 20; potassium fluoride, 46; G-1-P, pH 7.3, sene. Homogenization was carried out with a teflon 10; glycogen, 2 mg.; AMP, 0.04; 10 per cent ho pestle turning at about 600 r.p.m. for exactly 3 mogenate, 0.1 ml. The amount of inorganic phos minutes. The supernatant fluid was obtained by phate liberated was estimated according to Fiske centrifuging the tissue homogenates at 100,000 and Subbarow, with the presence or absence of Xg for 35 minutes at 00 C. A refrigerated Spin 5'-AMP used as a measure of the phosphorylase CO Model L centrifuge was used. About 1 gm. of a and b activities in the tissue extracts. tissue was added to hot KOH for glycogen esti Glycogen was isolated from hot KOH as de mation. scribed by Good, Kramer, and Somogyi (9) and, Glycogen synthetase and UDPG pyrophos after acid hydrolysis, estimated as glucose by the phorylase in the homogenate were assayed the Nelson (26) method.. same day. The remaining enzyme solutions were For the determination of glucose and oligo divided in tubes and frozen at —20°C. saccharides the tissue was extracted with 70 per Downloaded from cancerres.aacrjournals.org on September 24, 2021. © 1962 American Association for Cancer Research. NIGAM et al.—Limiting Enzymes and Glycogen Storage 133 cent ethanol for 24 hr. at 0°—5°C.,centrifuged, of glucosyl oligosaceharides in the liver has been concentrated, and chromatographed. The individ shown by Fishman and Sie (7) and their origin ual sugars were eluted from the paper and esti traced by Olavarria (29) as owing to the presence mated as glucose, as described by Nigam and of enzymes in liver which make labeled maltose, Gin (27). maltotriose, maltotetraose, and other homologs RESULTS from glycogen-C'4. A rapid decrease in the con Glycogen content of tumors and of the liver and centration of the oligosaccharides during fasting muscle of normal and tumor-bearing animak.—The has also been reported (32). A situation similar to low content of glycogen in tumors has been re fasting occurred during the growth of the liver ported by LePage (18) and others (2, 10). In the tumor. Six days after the implantation of the case of hepatoma, it has been shown that tumor tumor the animal lost its store of glycogen, with formation brings a subsequent decrease in the a subsequent decrease in the oligosaccharides.
Load more

Recommended publications
  • We Have Previously Reported' the Isolation of Guanosine Diphosphate
    VOL. 48, 1962 BIOCHEMISTRY: HEATH AND ELBEIN 1209 9 Ramel, A., E. Stellwagen, and H. K. Schachman, Federation Proc., 20, 387 (1961). 10 Markus, G., A. L. Grossberg, and D. Pressman, Arch. Biochem. Biophys., 96, 63 (1962). "1 For preparation of anti-Xp antisera, see Nisonoff, A., and D. Pressman, J. Immunol., 80, 417 (1958) and idem., 83, 138 (1959). 12 For preparation of anti-Ap antisera, see Grossberg, A. L., and D. Pressman, J. Am. Chem. Soc., 82, 5478 (1960). 13 For preparation of anti-Rp antisera, see Pressman, D. and L. A. Sternberger, J. Immunol., 66, 609 (1951), and Grossberg, A. L., G. Radzimski, and D. Pressman, Biochemistry, 1, 391 (1962). 14 Smithies, O., Biochem. J., 71, 585 (1959). 15 Poulik, M. D., Biochim. et Biophysica Acta., 44, 390 (1960). 16 Edelman, G. M., and M. D. Poulik, J. Exp. Med., 113, 861 (1961). 17 Breinl, F., and F. Haurowitz, Z. Physiol. Chem., 192, 45 (1930). 18 Pauling, L., J. Am. Chem. Soc., 62, 2643 (1940). 19 Pressman, D., and 0. Roholt, these PROCEEDINGS, 47, 1606 (1961). THE ENZYMATIC SYNTHESIS OF GUANOSINE DIPHOSPHATE COLITOSE BY A MUTANT STRAIN OF ESCHERICHIA COLI* BY EDWARD C. HEATHt AND ALAN D. ELBEINT RACKHAM ARTHRITIS RESEARCH UNIT AND DEPARTMENT OF BACTERIOLOGY, THE UNIVERSITY OF MICHIGAN Communicated by J. L. Oncley, May 10, 1962 We have previously reported' the isolation of guanosine diphosphate colitose (GDP-colitose* GDP-3,6-dideoxy-L-galactose) from Escherichia coli 0111-B4; only 2.5 umoles of this sugar nucleotide were isolated from 1 kilogram of cells. Studies on the biosynthesis of colitose with extracts of this organism indicated that GDP-mannose was a precursor;2 however, the enzymatically formed colitose was isolated from a high-molecular weight substance and attempts to isolate the sus- pected intermediate, GDP-colitose, were unsuccessful.
    [Show full text]
  • On the Action of Fluorouracil on Leukemia Cells1
    [CANCER RESEARCH 26 Part 1, 1611-1615,August 1966] On the Action of Fluorouracil on Leukemia Cells1 ALLAN R. GOLDBERG, JOHN H. MACHLEDT, JR., AND ARTHUR B. PARDEE Department of Biology, Princeton University, Princeton, New Jersey Summary In the present study the lymphoid leukemia L1210 of the mouse and a FU-resistant line were investigated. The problem The uptake and metabolism of radioactive uracil, uridine, posed was to discover a site of FU inhibition in the sensitive phosphate, and 5-fluorouracil by the mouse L1210 leukemic cells. The results suggest that the "salvage" pathway of pyrimi leukocytes and a fluorouracil-resistant variant were investigated. dine synthesis (see Chart 1) is sensitive to FU, with a resulting The dual aims of the research were to locate a metabolic differ inhibition of nucleic acid synthesis in the sensitive cells. The re ence responsible for resistance, and to define the site of action of the inhibitor. The resistant cells possess a much less active "sal sistant cells do not depend on this pathway, and hence are not vage" pathway, from uracil to nucleic acids, owing to a weaker susceptible to the inhibitor. uridine phosphorylase activity. They depend on the de novo pathway for a supply of pyrimidine nucleotides. Also, the con Materials and Methods version of fluorouracil to phosphorylated derivatives and its Uracil-3H and uridine-3H were obtained from the New Eng incorporation into RNA is somewhat reduced. Fluorouracil is land Nuclear Corporation, 5-FU-3H from Schwarz BioResearch, postulated to be less effective against these cells because its main Inc., and Na2H32PO4from Volk Radiochemical Co.
    [Show full text]
  • Non-Enzymatic Synthesis of the Coenzymes, Uridine Diphosphate
    N O N - E N Z Y M A T I C S Y N T H E S I S OF THE C O E N Z Y M E S , U R I D I N E D I P H O S P H A T E G L U C O S E A N D C Y T I D I N E D I P H O S P H A T E C H O L I N E , A N D O T H E R P H O S P H O R Y L A T E D M E T A B O L I C I N T E R M E D I A T E S A. M A R , J. D W O R K I N , and J. ORO* Department of Biochemical and Biophysical Sciences, University of Houston, Houston, TX 77004, U.S.A. (Received 3 November, 1986) Abstract. The synthesis of uridine diphosphate glucose (UDPG), cytidine diphosphate choline (CDP- choline), glucose-l-phosphate (G1P) and glucose-6-phosphate (G6P) has been accomplished under simulated prebiotic conditions using urea and cyanamide, two condensing agents considered to have been present on the primitive Earth. The synthesis of UDPG was carried out by reacting G1P and UTP at 70 °C for 24 hours in the presence of the condensing agents in an aqueous medium. CDP-choline was obtained under the same conditions by reacting choline phosphate and CTP. G1P and G6P were synthesized from glucose and inorganic phosphate at 70°C for 16 hours.
    [Show full text]
  • Development, Uridine Diphosphate Glucose (UDPG), Pyrophosphorylase (EC 2.7.7.9)11 and Trehalose-6-Phosphate Synthetase (EC 2.3.1.15)
    PERIODS OF GENETIC TRANSCRIPTION REQUIRED FOR THE SYNTHESIS OF THREE ENZYMES DURING CELLULAR SLIME MOLD DEVELOPMENT* BY R. ROTH, t J. 1\I. ASHWORTH,4 AND M. SUSSMAN§ DEPARTMENT OF BIOLOGY, BRANDEIS UNIVERSITY, WALTHAM, MASSACHUSETTS Communicated by Sol Spiegelman, January 24, 1968 Various aspects of mRNA synthesis and stability have been examined in bacteria by permitting transcription to occur over a known, usually brief, period and then determining how much of a specific protein subsequently accumulates in the absence of further RNA synthesis. Thus, bacterial cells have been exposed to an inducer for very brief periods during which RNA synthesis could proceed normally and were then permitted to synthesize the enzyme de novo in the absence of both the inducer and further transcription. The latter restriction was ac- complished with base analogues,' uracil deprivation,2 actinomycin D,3 and by infection with lytic viruses.5 In an arginine- and uracil-requiring strain of E. coli infected with phage T6, protein and RNA synthesis were sequentially (and reversibly) restricted by successive precursor deprivations in order to study the accumulation of enzymes required for phage development.2 6 Under all of the above conditions, the amounts of enzymes synthesized were assumed to reflect in a simple fashion the over-all quantities and net concentrations of the correspond- irng mRNA species, and the subsequent decays of enzyme-forming capacity with time were assumed to reflect the manner in which the mRNA disappeared. This approach has also been exploited to investigate the transcriptive and translative events required for accumulation and disappearance of the enzyme uridine diphosphate galactose: polysaccharide transferase during slime mold development.
    [Show full text]
  • Biochemical Screening of Pyrimidine Antimetabolites I
    Biochemical Screening of Pyrimidine Antimetabolites I. Systems with Oxidative Energy Source* JOSEPHE. STONEANDVANR. POTTER (McArdle Memorial Laboratory, Medical School, University of Wisconsin, Madison, Wis.} Orotic acid (uracil-4-carboxylic acid) has been the livers were quickly excised and placed in a chilled bath of isotonic saline solution. A 20 per cent homogenate in chilled shown under both in vivo and in vitro conditions, 0.25 M sucrose was made with the use of an all-glass Potter- in both microorganisms and mammals, to be a pre Elvehjem homogenizer, and Ihis homogenate was centrifuged cursor of the mono-, di-, and triphosphate pyrim- at approximately 600 g for 10 minutes to remove nuclei and idine nucleotides, the pyrimidine coenzymes, and whole cells. also of the pyrimidine moieties in both ribo- and Portions of 0.8 ml. of the cytoplasmic liver fraction were deoxyribonucleic acid (5, 6, 11, 12, 13, 15-17). placed in 25-ml. Erlenmeyer flasks, each of which contained 2.20 ml. of a reaction mixture which had the following com This study was prompted by the current position: progress in the study of nucleic acid metabolism Potassium glutamate 15.0 Amóles and its relationship to tumor growth and metabo Potassium fumarate 6.0 /«moles lism. The purposes of this research are the Potassium pyruvate 15.0 /iiiiole-s selection of agents as possible components of KHjPO, 15.0 /¿moles sequential (9) or concurrent blocks (4), the clari MgCl2 9.0 /uñóles fication of biochemical pathways, and the develop Ribose-5-phosphate (RSP) 6.0 /¿moles Uridine-5-monophosphate (UMP-5') 1.0 /imoles ment of concepts and technics in a biochemical Orotic acid-6-C" 0.3 /tmoles approach to pharmacological research.
    [Show full text]
  • Nucleotide Sugars in Chemistry and Biology
    molecules Review Nucleotide Sugars in Chemistry and Biology Satu Mikkola Department of Chemistry, University of Turku, 20014 Turku, Finland; satu.mikkola@utu.fi Academic Editor: David R. W. Hodgson Received: 15 November 2020; Accepted: 4 December 2020; Published: 6 December 2020 Abstract: Nucleotide sugars have essential roles in every living creature. They are the building blocks of the biosynthesis of carbohydrates and their conjugates. They are involved in processes that are targets for drug development, and their analogs are potential inhibitors of these processes. Drug development requires efficient methods for the synthesis of oligosaccharides and nucleotide sugar building blocks as well as of modified structures as potential inhibitors. It requires also understanding the details of biological and chemical processes as well as the reactivity and reactions under different conditions. This article addresses all these issues by giving a broad overview on nucleotide sugars in biological and chemical reactions. As the background for the topic, glycosylation reactions in mammalian and bacterial cells are briefly discussed. In the following sections, structures and biosynthetic routes for nucleotide sugars, as well as the mechanisms of action of nucleotide sugar-utilizing enzymes, are discussed. Chemical topics include the reactivity and chemical synthesis methods. Finally, the enzymatic in vitro synthesis of nucleotide sugars and the utilization of enzyme cascades in the synthesis of nucleotide sugars and oligosaccharides are briefly discussed. Keywords: nucleotide sugar; glycosylation; glycoconjugate; mechanism; reactivity; synthesis; chemoenzymatic synthesis 1. Introduction Nucleotide sugars consist of a monosaccharide and a nucleoside mono- or diphosphate moiety. The term often refers specifically to structures where the nucleotide is attached to the anomeric carbon of the sugar component.
    [Show full text]
  • Purine Metabolism in Adenosine Deaminase Deficiency* (Immunodeficiency/Pyrimidines/Adenine Nucleotides/Adenine) GORDON C
    Proc. Nati. Acad. Sci. USA Vol. 73, No. 8, pp. 2867-2871, August 1976 Immunology Purine metabolism in adenosine deaminase deficiency* (immunodeficiency/pyrimidines/adenine nucleotides/adenine) GORDON C. MILLS, FRANK C. SCHMALSTIEG, K. BRYAN TRIMMER, ARMOND S. GOLDMAN, AND RANDALL M. GOLDBLUM Departments of Human Biological Chemistry and Genetics and Pediatrics, The University of Texas Medical Branch and Shriners Burns Institute, Galveston, Texas 77550 Communicated by J. Edwin Seegmiller, June 1, 1976 ABSTRACT Purine and pyrimidine metabolites were MATERIALS AND METHODS measured in erythrocytes, plasma, and urine of a 5-month-old infant with adenosine deaminase (adenosine aminohydrolase, Subject. A 5-month-old boy born on December 5, 1974 with EC 3.5.4.4) deficiency. Adenosine and adenine were measured severe combined immunodeficiency was investigated. Physical using newly devised ion exchange separation techniques and examination revealed enlarged costochondral junctions and a sensitive fluorescence assay. Plasma adenosine levels were sparse lymphoid tissue (5). The serum IgG (normal values in increased, whereas adenosine was normal in erythrocytes and parentheses) was 31 mg/dl (263-713); IgM, 8 mg/dl not detectable in urine. Increased amounts of adenine were (34-138); found in erythrocytes and urine as well as in the plasma. and IgA was less than 3 mg/dl (13-71). Clq was not detectable Erythrocyte adenosine 5'-monophosphate and adenosine di- by double immunodiffusion. The blood lymphocyte count was phosphate concentrations were normal, but adenosine tri- 200-400/mm3 with 2-4% sheep erythrocyte (E)-rosettes, 12% phosphate content was greatly elevated. Because of the possi- sheep erythrocyte-antibody-complement (EAC)-rosettes, 10% bility of pyrimidine starvation, pyrimidine nucleotides (py- IgG bearing cells, and no detectable IgA or IgM bearing cells.
    [Show full text]
  • Jimmunol.1401364.Full.Pdf
    Loss of Mouse P2Y4 Nucleotide Receptor Protects against Myocardial Infarction through Endothelin-1 Downregulation This information is current as Michael Horckmans, Hrag Esfahani, Christophe Beauloye, of September 25, 2021. Sophie Clouet, Larissa di Pietrantonio, Bernard Robaye, Jean-Luc Balligand, Jean-Marie Boeynaems, Chantal Dessy and Didier Communi J Immunol published online 16 January 2015 http://www.jimmunol.org/content/early/2015/01/16/jimmun Downloaded from ol.1401364 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on September 25, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2015 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Published January 16, 2015, doi:10.4049/jimmunol.1401364 The Journal of Immunology Loss of Mouse P2Y4 Nucleotide Receptor Protects against Myocardial Infarction through Endothelin-1 Downregulation Michael Horckmans,*,1 Hrag Esfahani,†,1 Christophe Beauloye,‡ Sophie Clouet,* Larissa di Pietrantonio,* Bernard Robaye,x Jean-Luc Balligand,† Jean-Marie Boeynaems,*,{ Chantal Dessy,†,2 and Didier Communi*,2 Nucleotides are released in the heart under pathological conditions, but little is known about their contribution to cardiac inflam- mation.
    [Show full text]
  • Biochemical Conversion of Uridine Diphosphate Glucose to Uridine Diphosphate 3-Ketoglucose by Washing Cells of Agrobacterium Tumefaciens
    Short Communication [Agr. Biol. Chem., Vol. 34, No. 2, p. 321324, 1970] Biochemical Conversion of Uridine Diphosphate Glucose to Uridine Diphosphate 3-Ketoglucose by Washing Cells of Agrobacterium tumefaciens Sugar phosphate had been generally assumed phosphate permease+) which is a mutant to be impermeable through surface layer of derived from a parent strain Agrobacterium bacterial cells. Recently, however, the ex tumefaciens IAM 1525 (Strs, glucose+, sucrose+, istence of inducible active transport system glucose 1-phosphate+) was used in this experi for L-ƒ¿-glycerophosphate and glucose 6- ment. Standard culture medium had the phosphate was demonstrated in Escherichia following composition: (NH4)2 SO4 100 mg, coli.1•`4) In our previous papers,5,6) biochemi urea 50 mg, NaCl 20mg, MgSO4•E7H2O 20mg, cal conversion of glucose 1-phosphate to 3- CaCl•E2H2O 10mg, 1.0M phosphate buffer ketoglucose 1-phosphate by intact cells of (pH 7.0) 5.0ml and sucrose 2g in 100ml. Agrobacterium tumefaciens was reported and Cultivation was carried out at 27•Ž with was proved to be composed of the following shaking on a reciprocal shaker. The cells three processes: 1) entry of the substrate into were harvested at the middle logarithmic the cells by an active transport mechanism, growth phase (0.4•`0.8mg dry cells per one 2) conversion of the substrate to the product ml of medium), washed three times with 5 by D-glucoside 3-dehydrogenase,7) and 3) mm Tris-chloride buffer (pH 8.2), suspended exit of the product to the reaction medium in the same buffer and used as the washing by an unidentical mechanism.
    [Show full text]
  • Supplemental Data
    Article Detecting early myocardial ischemia in rat heart by MALDI imaging mass spectrometry ALJAKNA KHAN, Aleksandra, et al. Abstract Diagnostics of myocardial infarction in human post-mortem hearts can be achieved only if ischemia persisted for at least 6-12 h when certain morphological changes appear in myocardium. The initial 4 h of ischemia is difficult to diagnose due to lack of a standardized method. Developing a panel of molecular tissue markers is a promising approach and can be accelerated by characterization of molecular changes. This study is the first untargeted metabolomic profiling of ischemic myocardium during the initial 4 h directly from tissue section. Ischemic hearts from an ex-vivo Langendorff model were analysed using matrix assisted laser desorption/ionization imaging mass spectrometry (MALDI IMS) at 15 min, 30 min, 1 h, 2 h, and 4 h. Region-specific molecular changes were identified even in absence of evident histological lesions and were segregated by unsupervised cluster analysis. Significantly differentially expressed features were detected by multivariate analysis starting at 15 min while their number increased with prolonged ischemia. The biggest significant increase at 15 min was observed for m/z 682.1294 (likely [...] Reference ALJAKNA KHAN, Aleksandra, et al. Detecting early myocardial ischemia in rat heart by MALDI imaging mass spectrometry. Scientific Reports, 2021, vol. 11, no. 1, p. 5135 DOI : 10.1038/s41598-021-84523-z PMID : 33664384 Available at: http://archive-ouverte.unige.ch/unige:150558 Disclaimer: layout of this document may differ from the published version. 1 / 1 Detecting Early Myocardial Ischemia in Rat Heart by MALDI Imaging Mass Spectrometry Online Supplementary Material for Scientific Reports Aleksandra Aljakna Khan1, Nasim Bararpour2,3, Marie Gorka4, Timothée Joye2,3, Sandrine Morel5, Christophe Montessuit5, Silke Grabherr1,2, Tony Fracasso1, Marc Augsburger1,2, Brenda R.
    [Show full text]
  • Vanylglycol Valine Uridine Diphosphate Gl0.084943556
    Supplementary material Gut Supplementary Table S6. All metabolites analyzed metabolome in PDAC patients Sample Label P value Fold change of SMAD4+/SMAD4- Vanylglycol 0.155424904 3.137179109 Valine 0.004642878 0.589837251 Uridine diphosphate gl0.084943556 0.263274997 Uric acid 0.090790719 1.393871126 Tyrosine 0.003182454 0.514460059 Tryptophan 0.066090634 0.663198946 Thymol 0.146640203 2.916828638 Threonine 0.005124039 0.393216791 Thiosulfate 0.051860669 1.635639445 Succinic acid 0.364992 1.133060182 Suberic acid 0.133965924 1.163132453 Stearic acid 0.005186541 1.652773292 Sorbitol 0.004383992 1.618952122 Serine 0.002722175 0.519593603 Salicyluric acid 0.01643565 0.397706161 Quinic acid 0.034892334 2.174700019 Pyroglutamic acid 0.02033026 0.785242233 Pyridoxamine 0.30175314 0.637267947 Pseudoephedrine 0.127542773 2.835197206 Proline 0.00322716 0.54718818 Phosphoenolpyruvic ac0.20082072 2.509884702 Phenylalanine 0.008564006 0.567069702 Perillic acid 0.139725472 2.556597234 Pentadecanoic acid 0.021040611 1.5166969 Palmitoleic acid 0.179346121 1.186205247 Palmitic acid 0.004373542 1.50182052 Oxidized glutathione 0.240508659 2.271313826 O-Phosphoethanolamin0.049351827 0.629273759 Niacinamide 0.198513534 0.661777552 N-Acetyl-L-aspartic ac0.017293677 0.303552837 N-Acetylaspartylglutam0.071688124 0 Myristic acid 0.002221367 1.470162064 Methionine sulfoxide 0.044238216 0.632447594 Methionine 0.006936405 0.400639788 Maltotetraose 0.215648863 2.353750497 Malonic acid 0.303649525 0.705638171 Malic acid 0.000391647 0.509161372 LysoPC(18:0) 0.365579666 0.829193518 LysoPC(16:1(9Z)) 0.227278337 0.641851413 LysoPC(15:0) 0.204327924 0.688919299 Lysine 0.001970791 0.591957216 Liang C, et al. Gut 2019; 0:1–13.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2016/0000075 A1 CANSEV Et Al
    US 2016.0000075A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0000075 A1 CANSEV et al. (43) Pub. Date: Jan. 7, 2016 (54) USE OF PYRIMIDINES INSTIMULATION OF (86). PCT No.: PCT/TR2014/OOOO51 PLANT GROWTH AND DEVELOPMENT AND S371 (c)(1) ENHANCEMENT OF STRESS TOLERANCE (2) Date: s Aug. 21, 2015 (71) Applicants: GULEN,Asuman CANSEV,(US); Mige (US); KESICI Hatice (30) Foreign ApplicationO O Priority Data ZENGIN, (US); Sergil ERGIN, Feb. 21, 2013 (TR 2013/02102 Yerleskesi, Eskisehir (TR); Mehmet E. 21. 2013 E. - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 2013/02103 CANSEV, (US); Nabi Alper Feb. 20, 2014 (TR) ................................. 2014/O1995 KUMRAL, (US); ULUDAG UNIVERSITESITEKNOLOUI Publication Classification TRANSFER OFSTCARET VE SANAYIANONIMSIRKETI, (51) Int. Cl. NILUFER, Bursa (TR) AOIN 43/54 (2006.01) (52) U.S. Cl. (72) Inventors: Asuman CANSEV, Bursa (TR); Hatice CPC AOIN 43/54 (2013.O1 GULEN, Bursa (TR); Mige " ( .01) KESICIZENGIN, Bursa (TR): Sergil (57) ABSTRACT ERGIN, Eskisehir (TR); Mehmet CANSEV, Bursa (TR): Nabi Alper Disclosed is the use of pyrimidines, especially uridine and KUMRAL, Bursa (TR) cytidine chemicals of pyrimidines in stimulation of plant growth and development, as well as use of pyrimidines espe (21) Appl. No.: 14/769,652 cially uridine in enhancement of stress tolerance, reduction of stress, repair of stress-related injury and inhibition of stress, (22) PCT Filed: Feb. 21, 2014 and the methods thereof. Patent Application Publication Jan. 7, 2016 Sheet 1 of 5 US 2016/0000075A1 NH2 O O NN NH NH N 1so N 1so N 1so H H H Cytosine Thymine Uracil - Figure 1 O O NH Ho- n-so HO O so O.
    [Show full text]